Press Releases
Expert Q&A: Samsung Biologics’ capabilities to advance ADC therapeutics
Developing and manufacturing Antibody-Drug Conjugates (ADCs) requires a deep expertise due to the complexity of linking a cytotoxic payload and the need for specialized containment measures.
In an interview with American Pharmaceutical Review, Marc Studer, Senior Director and Head of ADC/mRNA Operations, discusses how our integrated ADC services are designed to manage the complexity of cytotoxic payloads, conjugation processes, and containment requirements—while maintaining consistent product quality.
Learn how we can support the development and manufacturing of next-generation therapeutics.
Developing and manufacturing Antibody-Drug Conjugates (ADCs) requires a deep expertise due to the complexity of linking a cytotoxic payload and the need for specialized containment measures.
In an interview with American Pharmaceutical Review, Marc Studer, Senior Director and Head of ADC/mRNA Operations, discusses how our integrated ADC services are designed to manage the complexity of cytotoxic payloads, conjugation processes, and containment requirements—while maintaining consistent product quality.
Learn how we can support the development and manufacturing of next-generation therapeutics.